2DT.F Amneal Pharmaceuticals Inc

Healthcare Pharmaceuticals Frankfurt Exchange
18.60 EUR
Close of Nov 12, 2026
9.65 19.00
Market cap
EUR 6.48B
P/E
54.7x
P/B
13.54x
ROE
24.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 2DT.F undervalued?

Graham number

The Graham number of Amneal Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amneal Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Amneal Pharmaceuticals Inc yet.

Amneal Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, …

Full company profile